The changing expression of PD-1 and CTLA-4 during the symptomatic and recovery phases of AHA points to the protective effects of these inhibitory molecules, perhaps by suppressing the activity of cytotoxic T cells, thereby preventing the induced fulminant destruction of HAV-infected hepatocytes. The gene discussed is CTLA4; the disease is autoimmune hemolytic anemia.